ScreenerHero

ELTX Elicio Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · elicio.com
1.850USD-1.60%Mkt Cap: 48.62M $P/E: —

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap48.62M USD
Enterprise Value40.08M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-39.57M USD
Revenue/Share—
Last Price1.850 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees33
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.11
PEG—
EV/EBITDA-1.06
EV/Revenue—
P/S—
P/B5.19
EPS (TTM)-2.16
EPS (Forward)-1.69
52W Range
1.7151% of range16.00
52W High16.00 USD
52W Low1.715 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-2418.77%
ROA-153.01%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-36.95M USD
CapEx (TTM)16.00K USD
FCF Margin—
FCF Yield-45.90%
Net Debt-9.33M USD
Net Debt/EBITDA0.25
Balance Sheet
Debt/Equity8.87
Current Ratio2.77
Quick Ratio2.55
Book Value/Sh0.36 USD
Cash/Share0.89 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateJun 2, 2023
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)13.67 USD
Upside (mean)+638.7%
Target Range8.000 USD – 23.00 USD
8.000+638.7% to mean23.00
# Analysts3
Ownership
Shares Out.26.28M
Float19.20M
Insiders26.97%
Institutions16.25%
Short Interest
Short Ratio4.9d
Short % Float8.17%
Short % Out.6.34%
Shares Short1.67M
Short (prev mo.)1.68M
Technical
SMA 502.545 (-27.3%)
SMA 2007.374 (-74.9%)
Beta1.98
S&P 52W Chg16.45%
Avg Vol (30d)344.40K
Avg Vol (10d)273.80K
Technical Indicators
RSI (14)27.4
MACD-0.2445
MACD Signal-0.2991
MACD Hist.+0.0546
BB Upper2.216 USD
BB Middle1.947 USD
BB Lower1.678 USD
BB Width27.64%
ATR (14)0.1508 USD
Vol Ratio (20d)0.38x